Investigational drug · Phase 2
GNS561
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Cholangiocarcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "GNS561"
First trial start
2023
Aug 21, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GNS561", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cholangiocarcinoma
Approved drugs for the same conditions: Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "GNS561" as an intervention, largest first.
- A Study to Compare the Efficacy of GNS561 Versus Standard of Care in Patients With SARS-CoV-2 (COVID-19) InfectionPivotal-lookingStatus unknown
Genoscience PharmaIndustry
NCT04637828 · 178 participants (planned) · Start Nov 18, 2020 · Primary completion Jul 30, 2021
Drug: GNS561 · For: COVID-19
Sites: Marseille, France
- Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated CholangiocarcinomaRecruiting
GenfitIndustry
NCT05874414 · 98 participants (planned) · Start Aug 21, 2023 · Primary completion Dec 2027
Drug: GNS561 + Trametinib · For: Cholangiocarcinoma
Sites: Los Angeles, California; Orlando, Florida; Tampa, Florida · 11 sites in all
Genoscience PharmaIndustry
NCT03316222 · 50 participants · Start Apr 4, 2018 · Primary completion Jan 15, 2021
Drug: GNS561 · For: Hepatocellular Carcinoma; Cholangiocarcinoma, Intrahepatic
Sites: New York, New York; Brussels, Belgium; Grenoble, France · 5 sites in all
Genoscience PharmaIndustry
NCT05353894 · 27 participants (planned) · Start May 2, 2022 · Primary completion Nov 30, 2022
Drug: GNS561 oral tablets and capsules · For: Primary Liver Cancer
Sites: Marseille, France
Centre Leon BerardAcademic, hospital or other
NCT04333914 · 19 participants · Start Apr 15, 2020 · Primary completion Jul 6, 2021
Drug: Autophagy inhibitor (GNS651); Avdoralimab and 1 more · For: SARS-CoV-2 (COVID-19) Infection; Advanced or Metastatic Hematological or Solid Tumor
Sites: Lyon, France; Clermont-Ferrand, France; Lille, France · 12 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A targeted drug conjugate derived from GNS561 and a Pt(II) moiety for PPT1-mediated lysosomal autophagy inhibition in triple-negative breast Cancer.
Cai L, Ge X, Xu G, et al. · Bioorg Chem 2026
- CRISPR screen identifies autophagy inhibition (GNS561) as a PARP inhibitor (AZD5305) combination strategy in small cell lung cancer.
Yu T, Barayan R, Song L, et al. · Cancer Metab 2026
- PPT1 is a negative regulator of STING signaling in cancer cells and its inhibition reactivates immune surveillance in cold tumors.
Chowdhury SR, Parikh CN, Kaur AN, et al. · Proc Natl Acad Sci U S A 2025
- GNS561 (ezurpimtrostat), a small basic lipophilic molecule, prevents lupus phenotype in a pristane-induced lupus mouse model.
Toumi E, Bestion E, Militello M, et al. · Br J Pharmacol 2025
- Dual Regulation of Sprouty 4 Palmitoylation by ZDHHC7 and Palmitoyl-Protein Thioesterase 1: A Potential Therapeutic Strategy for Cisplatin-Resistant Osteosarcoma.
Huang T, Chen Y, Zhao Q, et al. · Research (Wash D C) 2025
- Divergent effects of acute and chronic PPT1 inhibition in melanoma.
Crissey MAS, Versace A, Bhardwaj M, et al. · Autophagy 2025
Also in development for Cholangiocarcinoma
- tinengotinibTT-00420Phase 36 trials
TransThera Sciences (Nanjing), Inc. · Prostate Cancer (CRPC), Cholangiocarcinoma, Hepatocellular Carcinoma (HCC)
- [18F]FAPI-74 PETPhase 33 trials
SOFIE · Esophageal Cancer, Gastric Cancer (GC), Gastroesophageal Junction
- CTX-009Phase 32 trials
Compass Therapeutics · Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer
- GV20-0251Phase 23 trials
GV20 Therapeutics · Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma, pMMR/MSS Adenocarcinoma of the Colon or Rectum
- certepetideCEND-1, LSTA1Phase 21 trial
Lisata Therapeutics, Inc. · Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma
- CGT4859Phase 21 trial
Cogent Biosciences, Inc. · Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult
- E7090Phase 21 trial
Eisai · Cholangiocarcinoma
- gavo-celPhase 21 trial
TCR2 Therapeutics · Mesothelioma, Mesothelioma, Malignant, Mesothelioma; Pleura
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.